SCIENTIFIC VALIDATION OF VIDANGADI GUGGULU IN DIABETES MELLITUS USING STREPTOZOTOCIN-INDUCED WISTAR RAT MODEL

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia and associated complications. In Ayurveda, diabetes is correlated with Prameha, and Vidangadi Guggulu is traditionally indicated for Meha as per classical texts (Chakradatta, 44/69-70).[10] Despite its traditional use, experimental validation is limited. The present study evaluated the antihyperglycaemic activity of Vidangadi Guggulu in streptozotocin (STZ)-induced diabetic Wistar rats. Twenty-four healthy adult Wistar albino male rats were divided into four groups (n = 6): normal control, diabetic control, standard drug treated (Metformin 100 mg/kg, p.o.), and test drug treated (Vidangadi Guggulu 50 mg/kg, p.o.). Diabetes was induced by a single intraperitoneal injection of STZ (40 mg/kg). Fasting blood glucose (FBG) was measured at baseline, after STZ induction, and after 14 days of treatment. STZ administration caused significant hyperglycaemia in all diabetic groups. Treatment with Vidangadi Guggulu significantly reduced FBG levels (63.98%), comparable to Metformin (69.41%) (p < 0.001). These results suggest that Vidangadi Guggulu, as described in Chakradatta (44/69-70), possesses significant antihyperglycaemic activity, supporting its traditional use in the management of Prameha. Further studies are needed to confirm its therapeutic potential in humans. Keywords: Vidangadi Guggulu, Meha, Prameha, Diabetes mellitus, Streptozotocin, Antihyperglycaemic activity, Antidiabetic activity